Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s MEK Inhibitor Boosts PFS, But Misses Overall Survival Endpoint In Lung Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

MEK inhibitor selumetinib improves progression-free survival in KRAS mutation-positive metastatic non-small cell lung cancer, hitting secondary endpoints. But the drug missed the overall survival primary endpoint.

You may also be interested in...

AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key

AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.

Over A Decade In The Making, MEK Inhibitors Break Through In Melanoma

As if moving on from failures of the past, MEK inhibitors are now being positioned as part of the next standard of care in BRAF-mutant melanoma. Glaxo prepares to file trametinib as a monotherapy in 2012, after reporting striking Phase III results, while Novartis/Array’s MEK 162 demonstrates value in area of unmet need.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts